AI Article Synopsis
- A 53-year-old man was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) after experiencing shoulder swelling and pain.
- Genetic testing showed that he had mutations in STK11 and KEAP1, but did not have any KRAS mutations.
- The patient did not respond to multiple cancer treatments, suggesting that the STK11 and KEAP1 mutations may contribute to resistance against therapies in KRAS wild-type NSCLC.
Article Abstract
We herein report a patient with KRAS wild-type non-small-cell lung cancer (NSCLC) with concurrent STK11 and KEAP1 mutations. A 53-year-old man visited a local doctor with a complaint of left shoulder swelling and pain. He was diagnosed with NSCLC cT4N0M1c stage IVB. A comprehensive genome profile test revealed mutations in STK11 and KEAP1 but no KRAS mutations. The patient was refractory to radiotherapy, immunotherapy, and chemotherapy. Thus, STK11 and KEAP1 mutations can be considered resistance mutations that confer resistance to various anticancer therapies in KRAS wild-type NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641186 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.1110-22 | DOI Listing |
Publication Analysis
Top Keywords
stk11 keap1
16
kras wild-type
12
mutations stk11
8
wild-type non-small-cell
8
non-small-cell lung
8
lung cancer
8
keap1 mutations
8
mutations
5
concurrent mutations
4
stk11
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!